Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s Laboratories Limited (NYSE:RDY) and Alvotech announced that they have entered into a ...

Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), ...

Alvotech (ALVO) has been on a downward spiral lately with significant selling pressure. After declining 6.6% over the past ...

Inventiva named Jason Campagna as president of R&D and chief medical officer, and Martine Zimmermann as EVP of regulatory affairs and quality assurance. Evolent named Dr. David Lim as chief clinical ...

Q1FY26 revenues at ?12.7 billion, YoY growth of 142% and flat QoQ growth. This includes revenues from the acquired NRT business.

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...

The "Ophthalmics Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of 344 ophthalmics ...

Detailed price information for Dr. Reddy's Laboratories Ltd ADR (RDY-N) from The Globe and Mail including charting and trades.

Dr. Reddy's reports Q1 earnings on July 23. before market open. Over the last 1 year, RDY has beaten EPS estimates 75% of the time and has beaten revenue estimates 100% of the time.